Today’s top gainers include the company Medivation, Inc. (NASDAQ:MDVN) which is in the industry Biotechnology, gaining 19.71% today. In the last week its performance is 1.73%, and 10.90% for the past quarter. Currently, Medivation, Inc., MDVN has a target price of 67, so today’s gain of 19.71% is a significant step towards its target price. The GAP today is therefore 20.04%.
Medivation, Inc. (NASDAQ:MDVN), has a market cap of 11148.56, and is based in USA. Insider ownership is at 1.10%, and institutional ownership is 91.10%.
At the current price of 80.4, it has a dividend yield of *TBA, and its target price is 67. This is with a profit margin of -17.20%, and total debt/equity of 0. Medivation, Inc. (NASDAQ:MDVN) has a P/E of *TBA, as well as a forward P/E of 30.81.
With a current EPS of -1.17, and a forecasted EPS growth for next year at 70.98%,Medivation, Inc. (NASDAQ:MDVN) has had a EPS growth for the past five years at 50.90%. For the next five years EPS growth is projected to be 37.68%.
Performance for the year is 45.60%. Since its IPO date on 1/13/1997, the total performance to date is 38.93%.
Volume today for Medivation, Inc. (NASDAQ:MDVN), is 39017622, while its average volume is 2092.9. Whilst the total gain today was 19.71%, it did have a day high of 17.60%.
Volatility for this week has been at 1.94%, and 1.81% for the month. The 52-week low for Medivation, Inc., MDVN has been 204.43%, while the 52-week-high has reached 17.60%.
Looking at its return of investments, which is 27.10%, and its return on assets is -13.00%. Medivation, Inc. (NASDAQ:MDVN) has an operating margin of -26.30%. With a sales growth of 17.40% quarter over quarter. Bearing in mind that Medivation, Inc., MDVN is in the sector Healthcare, its long-term debt/equity is 0, and has a current ratio of 4.3 and 4.3 for quick ratio.
So what is the value of Medivation, Inc.? Well its PEG is *TBA, and the P/S is 10.85, along with a P/B of 20.73. Meanwhile it has a p/cash of 34.07.